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Available online at www.sciencedirect.comAcquisition of exogenous DNA by pathogenic bacteria
represents the basis for much of the acquired antimicrobial
resistance in pathogenic bacteria. A more extreme mechanism to
avoid the effect of an antibiotic is to delete the drug target,
although this would be predicted to be rare since drug targets are
often essential genes. Here, we review and discuss the
description of a novel mechanism of resistance to the
cephalosporin drug ceftazidime caused by loss of a penicillin-
binding protein (PBP) in a Gram-negative bacillus (Burkholderia
pseudomallei). This organism causes melioidosis across south-
east Asia and northern Australia, and is usually treated with two or
more weeks of ceftazidime followed by oral antibiotics for three to
six months. Comparison of clinical isolates from six patients with
melioidosis found initial ceftazidime-susceptible isolates and
subsequent ceftazidime-resistant variants. The latter failed to
grow on commonly used culture media, rendering these isolates
difficult to detect in the diagnostic laboratory. Genomic analysis
using pulsed-field gel electrophoresis and array based genomic
hybridisation revealed a large-scale genomic deletion comprising
49 genes in the ceftazidime-resistant strains. Mutational analysis
of wild-type B. pseudomallei demonstrated that ceftazidime
resistance was due to deletion of a gene encoding a PBP 3
present within the region of genomic loss. This provides one
explanation for ceftazidime treatment failure, and may be a
frequent but undetected event in patients with melioidosis.
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Introduction
Acquisition of exogenous DNA by pathogenic bacteria
represents the basis for the inexorable increase in the
Open access under CC BY license.www.sciencedirect.com prevalence of resistance to numerous classes of antimi-
crobial drugs in a wide range of bacterial species [1].
Students of microbiology are taught the mechanisms of
DNA acquisition at an early stage in their training, an
understanding of which represents one of the most useful
and durable set of principles for those who are interested
in the biology of antibiotic resistance. The three mech-
anisms are transformation (direct uptake of exogenous
DNA), conjugation (transfer of genetic material such as
plasmids and transposons by direct cell-to-cell contact),
and transduction (introduction of new genes via phage)
[1]. Introduction of new DNA may be associated with a
fitness cost to the bacterium, but any disadvantage may be
overcome in settings where the new phenotype provides a
selective advantage. Healthcare settings are a case in
point, where the emergence of a bacterial strain with a
specific drug-resistant phenotype in response to antibiotic
pressure may lead to clonal expansion and replacement of
pre-existing strains. A good example is methicillin-resist-
ance Staphylococcus aureus (MRSA), a resistant phenotype
that results from the acquisition of a genetic element
containing mecA encoding an altered penicillin-binding
protein (PBP 2a) with lower affinity for all b-lactam
antibiotics [2]. Much of the clinically relevant drug resist-
ance arising in Gram-negative bacilli is due to gene
acquisition, and includes the spread via mobile genetic
elements of extended spectrum beta-lactamases [3] and
carbapenemases [4]. A recent important example is the
emergence and spread of Gram-negative bacteria positive
for NDM-1 (New Delhi metallo-beta-lactamase) [5],
which confers resistance to the carbapenem drugs, the
drug class of choice for a range of situations where in-
fection is potentially life threatening [6].
An alternative mechanism of antibiotic resistance is
through mutation in existing gene(s) that encode the
drug target. The development of resistance depends on
the introduction of a mutation that leads to a fundamental
change in the interaction between the drug and its
bacterial target. For example, rifampicin, which is a broad
spectrum antibiotic active against Mycobacterium tubercu-
losis and other bacterial pathogens, targets the DNA-
dependent RNA polymerase b subunit, and resistance
arises as a result of a mutation in the rpoB gene that
encodes the rifampicin binding area [7]. A more extreme
mechanism by which a bacterium could avoid the effect
of an antibiotic is to delete the drug target altogether.
This would be predicted to be extremely uncommon
since drug targets are often essential genes, and gene
loss would only be possible in the event that the function
of the deleted gene could be performed by alternativeCurrent Opinion in Microbiology 2012, 15:583–587
584 Antimicrobialsgenes or gene pathways. Here, we review and discuss the
description of a novel mechanism of resistance to the
cephalosporin drug ceftazidime based on loss of a PBP in
a Gram-negative bacillus (Burkholderia pseudomallei).
B. pseudomallei and melioidosis
B. pseudomallei is an environmental bacterium and the
cause of melioidosis [8]. This infection is most com-
monly seen in south-east Asia and northern Australia but
has been reported worldwide, particularly in travellers
returning from areas where meliodiosis is endemic. In-
fection can present with a wide spectrum of clinical
features including septicaemia, pulmonary infection,
intra-abdominal abscesses and disseminated infection
[8]. B. pseudomallei is intrinsically resistant to a range
of antibiotics including gentamicin, streptomycin, rifam-
picin and many b-lactams. Reported resistance mechan-
isms include bacterial cell membrane impermeability [9],
mutations in the antibiotic target site [10], enzymatic
inactivation [11,12], and multi-drug efflux pumps
[13,14]. The majority of B. pseudomallei isolates are
susceptible to ceftazidime, trimethoprim-sulfamethoxa-
zole, amoxicillin-clavulanate, imipenem and meropenem
[15,16]. Antimicrobial therapy for melioidosis is required
for three to six months to achieve cure, and is divided into
an intravenous phase of ceftazidime or a carbapenem drug
for two weeks (or longer if clinically indicated), followed
by oral trimethoprim-sulfamethoxazole or amoxillin-cla-
vulanate [17]. The switch from parenteral to oral anti-
microbial therapy is made once the patient shows clear
evidence of clinical improvement, including an absence
of fever for 48 hours and negative repeat blood culture
taken at around one week after the onset of therapy.
Prolonged parenteral therapy may be required for
patients with disseminated infection, involvement of
the central nervous system, bone or joint, and patients
with deep-seated abscesses that cannot be drained.
Despite the length of treatment, eradication of B. pseu-
domallei is notoriously difficult and high rates of clinical
failure during the period of therapy and relapse from a
persistent focus after antibiotics are stopped have been
reported [18], although the basis for this is not under-
stood. One possible explanation is the development of
antibiotic resistance during therapy in a previously
susceptible isolate (secondary resistance). No (primary
or secondary) resistance to the carbapenem drugs has
been reported in the published literature to date [15],
while secondary resistance to ceftazidime has been
reported in a very small number of cases; the mechanisms
in some of these cases have been defined as mutations in
the penA gene that encodes class A b-lactamase PenA and
alters substrate specificity [19].
Secondary resistance to ceftazidime in
B. pseudomallei
The clinical narrative to this story starts in 2006, when a
patient presented to a hospital in northeast Thailand withCurrent Opinion in Microbiology 2012, 15:583–587 culture-confirmed melioidosis [20]. B. pseudomallei was
isolated from blood cultures, and was unremarkable in its
growth characteristics and colonial appearance and was
susceptible to ceftazidime. The patient was commenced
on ceftazidime, but remained febrile after several weeks of
therapy and underwent a splenectomy for large and per-
sistent splenic abscesses. A subsequent blood culture taken
on day 36 of ceftazidime treatment was culture negative on
blood agar but grew pinpoint colonies after 48 hours of
incubation on a solid medium called Ashdown agar, a
selective medium used specifically for the culture of B.
pseudomallei [21]. The colonial morphology was unusual
for B. pseudomallei (which normally produces characteristic
‘cornflower head’ colonies), and Gram stain revealed
Gram-negative filaments. Identification using routine bio-
chemical tests was unsuccessful because of very poor
bacterial growth, but a monoclonal antibody-based latex
agglutination test to B. pseudomallei exopolysaccharide was
positive [22]. Antimicrobial therapy was changed to oral
trimethoprim-sulfamethoxazole, the patient became afeb-
rile and was discharged from hospital on day 53. Two
similar cases occurred in 2007 and examination of labora-
tory records identified three further cases (six cases in
total), all of whom had been treated with prolonged cefta-
zidime therapy (median 26.5 days, range 18–36 days), had
failed to respond to therapy, and grew a bacterial variant
that was similar to the first case. The highly atypical
morphological appearance on solid agar would almost
certainly result in most such cultures being considered
as contaminants of no clinical significance.
A series of simple growth experiments were performed on
pairs of isolates from the six cases (first isolate to be
cultured on admission and subsequent variant strain),
to test whether these grew on commonly used bacterio-
logical media. The admission isolates had typical growth
characteristics and colonial morphology on a range of solid
media including blood agar, Columbia agar, Mueller-
Hinton agar, tryptone soya agar, Burkholderia cepacia agar,
Luria–Bertani agar and Ashdown agar (Figure 1a). These
also grew in commercial blood culture bottles, tryptone
soya broth and Mueller-Hinton broth. In contrast, despite
prolonged incubation for seven days at 37 8C, the variant
isolates failed to grow on any of the media apart from
Ashdown agar, on which pinpoint colonies were seen after
48 hours’ incubation (Figure 1d). The six variant strains
also failed to grow in the commercial blood culture bottles
or tryptone soya broth. This finding has major implica-
tions for clinical care, since it is highly likely that culture
of samples containing variant B. pseudomallei would be
falsely negative. Gram stain of the admission isolates was
typical for the species (Figure 1b), but Gram stain of all of
the variant isolates showed Gram-negative filaments
(Figure 1e). In the diagnostic laboratory, this appearance
would mean that B. pseudomallei would not be considered.
Real-time microscopy (RTM-3) which allows visualiza-
tion of live bacteria in the absence of stains (or fixatives)www.sciencedirect.com
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Comparison of the appearance of an initial ceftazidime-susceptible B. pseudomallei strain 415a and the ceftazidime-resistant variant strain 415e
isolated from the same patient after prolonged ceftazidime therapy. Colony morphology (a and d), Gram stain and light microscopy (b and e), and
unstained appearance by real-time microscopy (c and f) of initial (a to c) and variant strain (d to f). Colony morphology was observed after spread
plating on Ashdown agar and incubation for 4 days at 37 8C in air. Gram stain was observed through a 40 objective. Real-time microscopy was
performed using a real time microscope (RTM-3) at 1000 magnification. Reproduced with permission from Chantratita et al. [20].of the six initial strains demonstrated motile bacilli
(Figure 1c), whereas the six variant strains were nonmo-
tile filaments with an appearance consistent with the
presence of septa in the absence of cell division
(Figure 1f).
Antimicrobial susceptibility testing was performed on the
six isolate pairs; this confirmed that the admission isolates
were susceptible to ceftazidime but that the variants were
highly resistant (minimum inhibitory concentration
[MIC] > 256 mg/ml). MICs for other antimicrobial classes
demonstrated that within-pair MICs were comparable for
the six isolate pairs (including amoxillin-clavulanate),
indicating that the defect appeared to be specific to
ceftazidime. Resistance most likely arose in vivo during
ceftazidime therapy, a suggestion supported by genotyp-
ing data which showed that isolate pairs from the same
patient were the same genotype (as defined by multilocuswww.sciencedirect.com sequence typing). Each patient was infected with a
different genotype, however, suggesting that the ceftazi-
dime-resistant variant had arisen independently in sev-
eral lineages. Two of the six patients died, which is
comparable to the crude mortality rate from melioidosis
in the same hospital setting. This suggests that the
variants remained virulent in the human host despite
the obvious growth defects under in vitro conditions.
Gain of resistance through gene loss
Sequencing of the penA gene of the admission and variant
isolates failed to identify any de novo genetic changes in
the penA gene, suggesting a novel resistance mechanism.
Comparison of the banding pattern produced by pulsed-
field gel electrophoresis (PFGE) [23] between each strain
pair showed a loss of a 150 kb band in four of the six
variant strains, suggesting a large genomic deletion. This
was further investigated by array based comparativeCurrent Opinion in Microbiology 2012, 15:583–587
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two chromosomes, and aCGH demonstrated a genomic
deletion in chromosome 2 in all six variant strains. These
ranged in size from 145 kb to 309 kb, with a minimal
common region of genomic loss of 71 kb comprising 49
genes. PCR and sequencing in the region of the putative
deletion were used to confirm the deletion. Analysis of
the flanking sequences did not identify any distinct
motifs associated with breakpoints, suggesting that the
most likely mechanism was random recombination in the
presence of ceftazidime.
The common deleted region included three genes that
were potential candidates for the resistant phenotype —
two encoded penicillin-binding proteins of the PBP 3
family, and the third encoded a putative D-alanyl-D-ala-
nine carboxypeptidase that belongs to the PBP 5/6 family.
Mutants were made in each gene using a laboratory strain
of B. pseudomallei, which implicated one of the PBP 3
genes (BPSS1219). After a series of complex molecular
steps to circumvent what appeared to be a lethal mutation
when BPSS1219 was rendered detective, this gene was
shown to be associated with the growth detect, filamenta-
tion, and resistance to ceftazidime [20]. This finding is
compatible with several lines of evidence in the literature.
In other Gram-negative bacilli including Escherichia coli
and Pseudomonas aeruginosa, ceftazidime owes its antibac-
terial activity to a high affinity for PBP 3 [25]. In addition,
inactivation of PBP 3 in E. coli results in inhibition of cell
division and growth into long filaments [26,27]. The
growth defect of the variant B. pseudomallei with very
slow growth on Ashdown agar but no other media may be
related to osmotic effects and bacterial lysis, with growth
on Ashdown being supported by the presence of 4%
glycerol.
Gene loss and gene gain by B. pseudomallei
The B. pseudomallei genome is highly dynamic, with
around 15% of the genome being variably present across
isolates [28–30]. The variable region includes multiple
genomic islands containing DNA acquired from other
bacteria. There is also existing evidence for genetic
divergence of B. pseudomallei during human infection,
which was demonstrated by genotyping multiple colonies
from several tissue sites of patients with acute melioidosis
[31]. Natural, large-scale deletion of genomic material in
B. pseudomallei has been reported once before [32]. B.
pseudomallei is intrinsically resistant to gentamicin, and
deletion of a region of >130 kb including the amrAB-oprA
operon is the basis for gentamicin-susceptible strains (a
phenotype which occurs in 1 in 1000 clinical isolates)
which remain virulent in patients.
Concluding comments
Gene deletion is an extreme and rare mechanism of gain
of resistance to antimicrobial drugs. A fascinating and
clinically relevant twist to the story recounted here is thatCurrent Opinion in Microbiology 2012, 15:583–587 the resistant B. pseudomallei variants were rendered
almost undetectable in the diagnostic microbiology
laboratory. It remains to be seen as to what proportion
of patients who fail ceftazidime therapy for melioidosis
fall into the category of having such a variant.
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